

**Supplementary Table III.** Newcastle-Ottawa quality assessment form for case control studies

No	Author/year	Selection				Comparability	Outcome			Total score	Quality score
		S1	S2	S3	S4		O1	O2	O3		
<i>AGT-rs699</i>											
1	Kishimoto <i>et al</i> (2001)	*	*	*	*	*	*	*	*	8	Good
2	Kario <i>et al</i> (1999)	*	*	*	*	*	*	*		7	Good
3	Iso <i>et al</i> (2000)	*	*	*	*	*	*	*	*	8	Good
4	Sato <i>et al</i> (2000)	*	*	*	*	*	*	*	*	8	Good
5	Kato <i>et al</i> (2000) <sup>21</sup>	*	*	*	*	*	*	*	*	8	Good
6	Kato <i>et al</i> (1999)	*	*	*	*	*	*	*	*	8	Good
7	Morise <i>et al</i> (1995)	*	*	*	*	*	*	*		7	Good
8	Hata <i>et al</i> (1994)	*	*	*	*	*	*	*	*	8	Good
9	Wang <i>et al</i> (2014) <sup>40</sup>	*	*	*	*	*	*	*	*	8	Good
10	Li <i>et al</i> (2014)	*	*	*	*	*	*	*	*	8	Good
11	Hu <i>et al</i> (2014)	*	*	*	*	*	*	*		7	Good
12	Najatizadeh <i>et al</i> (2008)	*	*	*	*	*	*	*		7	Good
13	Kohli <i>et al</i> (2016)	*	*	*	*	*	*	*		7	Good
14	Ramu <i>et al</i> (2011)	*	*	*	*	*	*	*		7	Good
15	Padma <i>et al</i> (2015)	*	*	*	*	*	*	*	*	8	Good
16	Charita <i>et al</i> (2012)	*	*	*	*	*	*	*	*	8	Good
17	Vamsietal.(2012)	*	*	*	*	*	*	*		7	Good
18	Singh <i>et al</i> (2014)	*	*	*	*	*	*	*		7	Good
19	Srivastava <i>et al</i> (2012)	*	*	*	*	*	*	*		7	Good
20	Thomas <i>et al</i> (2000)	*	*	*	*	*	*	*	*	8	Good
21	Cheung <i>et al</i> (1998) <sup>22</sup>	*	*	*	*	*	*	*		7	Good
22	Fang <i>et al</i> (2010)	*	*	*	*	*	*	*		7	Good
23	Wu <i>et al</i> (2004)	*	*	*	*	*	*	*	*	8	Good
24	Agachan <i>et al</i> (2003)	*	*	*	*	*	*	*	*	8	Good
25	Saab <i>et al</i> (2011)	*	*	*	*	*	*	*		7	Good
26	Frossard <i>et al</i> (1998)	*	*	*	*	*	*	*		7	Good
27	Hingorani <i>et al</i> (1996)	*	*	*	*	*	*	*	*	8	Good
28	Patricia <i>et al</i> (1998)	*	*	*	*	*	*	*		7	Good
29	Mondorf <i>et al</i> (1998)	*	*	*	*	*	*	*	*	8	Good
30	Kiema <i>et al</i> (1996)	*	*	*	*	*	*	*		7	Good
31	Pe'rez <i>et al</i> (2000)	*	*	*	*	*	*	*	*	8	Good
32	Maja <i>et al</i> (2006)	*	*	*	*	*	*	*		7	Good
33	Vas'ku <i>et al</i> (2002)	*	*	*	*	*	*	*	*	8	Good
34	Vana <i>et al</i> (2015)	*	*	*	*	*	*	*		7	Good
35	Procopcuic <i>et al</i> (2002)	*	*	*	*	*	*	*	*	8	Good
36	Begra <i>et al</i> (2002) <sup>26</sup>	*	*	*	*	*	*	*		7	Good
37	Jeunemaitre <i>et al</i> (1993)	*	*	*	*	*	*	*	*	8	Good
38	Caulfield <i>et al</i> (1994)	*	*	*	*	*	*	*		7	Good
39	Berocki <i>et al</i> (1997)	*	*	*	*	*	*	*	*	8	Good

*Contd...*

No	Author/year	Selection				Comparability	Outcome			Total score	Quality score
		S1	S2	S3	S4		O1	O2	O3		
41	Sunder <i>et al</i> (2002)	*	*	*	*	*	*	*		7	Good
42	Vasku <i>et al</i> (1998)	*	*	*	*	*	*	*	*	8	Good
43	Barley <i>et al</i> (1994)	*	*	*	*	*	*	*	*	8	Good
44	Jeunemaitre <i>et al</i> (1997)	*	*	*	*	*	*	*		7	Good
45	Glavnik <i>et al</i> (2007)	*	*	*	*	*	*	*		7	Good
46	Freitas <i>et al</i> (2007)	*	*	*	*	*	*	*	*	8	Good
47	Bautista <i>et al</i> (2008)	*	*	*	*	*	*	*		7	Good
48	Fardella <i>et al</i> (1998) <sup>23</sup>	*	*	*	*	*	*	*		7	Good
<i>CYP11B2</i> -rs1799998											
1	Zhu <i>et al</i> (2003)	*	*	*	*	*	*	*	*	8	Good
2	Hlubocka <i>et al</i> (2009)	*	*	*	*	*	*	*	*	8	Good
3	Castellano <i>et al</i> (2003)	*	*	*	*	*	*	*		7	Good
4	Staessen <i>et al</i> (2001)	*	*	*	*	*	*	*		7	Good
5	Bengra <i>et al</i> (2002) <sup>26</sup>	*	*	*	*	*	*	*	*	8	Good
6	Chen <i>et al</i> (2011)	*	*	*	*	*	*	*	*	8	Good
7	Niu <i>et al</i> (2010)	*	*	*	*	*	*	*		7	Good
8	Muli <i>et al</i> (2011)	*	*	*	*	*	*	*		7	Good
9	Li <i>et al</i> (2014) <sup>13</sup>	*	*	*	*	*	*	*	*	8	Good
10	Li <i>et al</i> (2016)	*	*	*	*	*	*	*	*	8	Good
11	Ji <i>et al</i> (2015)	*	*	*	*	*	*	*	*	8	Good
12	Gu <i>et al</i> (2004)	*	*	*	*	*	*	*		7	Good
13	Sun <i>et al</i> (2011)	*	*	*	*	*	*	*	*	8	Good
14	Tsujita <i>et al</i> (2001)	*	*	*	*	*	*	*	*	8	Good
15	Tsukada <i>et al</i> (2002)	*	*	*	*	*	*	*	*	8	Good
16	Komiya <i>et al</i> (2000)	*	*	*	*	*	*	*	*	8	Good
17	Kato <i>et al</i> (2000) <sup>21</sup>	*	*	*	*	*	*	*		7	Good
18	Patnaik <i>et al</i> (2014)	*	*	*	*	*	*	*	*	8	Good
19	Rajput <i>et al</i> (2005)	*	*	*	*	*	*	*	*	8	Good
20	Azim <i>et al</i> (2010)	*	*	*	*	*	*	*		7	Good
21	Rajan <i>et al</i> (2010)	*	*	*	*	*	*	*	*	8	Good
22	Vamsi <i>et al</i> (2016)	*	*	*	*	*	*	*	*	8	Good
23	Tiwari <i>et al</i> (2014)	*	*	*	*	*	*	*		7	Good
<i>ADRB2</i> -rs1042713											
1	Jia <i>et al</i> (2000)	*	*	*	*	*	*	*	*	8	Good
2	Timmermann <i>et al</i> (1998)	*	*	*	*	*	*	*	*	8	Good
3	Xie <i>et al</i> (2000)	*	*	*	*	*	*	*		7	Good
4	Filigheddu <i>et al</i> (2004)	*	*	*	*	*	*	*		7	Good
5	Bartels <i>et al</i> (2007) <sup>37</sup>	*	*	*	*	*	*	*		7	Good
6	Poojaga <i>et al</i> (2006) <sup>19</sup>	*	*	*	*	*	*	*	*	8	Good
7	Sunder <i>et al</i> (2002)	*	*	*	*	*	*	*		7	Good
8	Castellano <i>et al</i> (2003)	*	*	*	*	*	*	*	*	8	Good

*Contd...*

No	Author/year	Selection				Comparability	Outcome			Total score	Quality score
		S1	S2	S3	S4		O1	O2	O3		
9	Herrmann <i>et al</i> (2002)	*	*	*	*	*	*	*	*	8	Good
10	Herrmann <i>et al</i> (2000)	*	*	*	*	*	*	*		7	Good
11	Tang <i>et al</i> (2003)	*	*	*	*	*	*	*		7	Good
12	Xie <i>et al</i> (2000)	*	*	*	*	*	*	*	*	8	Good
13	Herrmann <i>et al</i> (2000)	*	*	*	*	*	*	*		7	Good
14	Tang <i>et al</i> (2003)	*	*	*	*	*	*	*		7	Good
15	Lou <i>et al</i> (2011) <sup>20</sup>	*	*	*	*	*	*	*	*	8	Good
16	Yu <i>et al</i> (2008)	*	*	*	*	*	*	*	*	8	Good
17	Kato <i>et al</i> (2001)	*	*	*	*	*	*	*	*	8	Good
18	Misanoa <i>et al</i> (2009)	*	*	*	*	*	*	*	*	8	Good
<i>ADRB2-rs1042714</i>											
1	Jia <i>et al</i> (2000)	*	*	*	*	*	*	*		7	Good
2	Bartels <i>et al</i> (2007) <sup>37</sup>	*	*	*	*	*	*	*		7	Good
3	Pojaga <i>et al</i> (2006) <sup>19</sup>	*	*	*	*	*	*	*	*	8	Good
4	Castellano <i>et al</i> (2003)	*	*	*	*	*	*	*	*	8	Good
5	Sunder <i>et al</i> (2002)	*	*	*	*	*	*	*	*	8	Good
6	Herrmann <i>et al</i> (2002)	*	*	*	*	*	*	*		7	Good
7	Xie <i>et al</i> (2000)	*	*	*	*	*	*	*	*	8	Good
8	Lou <i>et al</i> (2011) <sup>20</sup>	*	*	*	*	*	*	*	*	8	Good
9	Yu <i>et al</i> (2008)	*	*	*	*	*	*	*		7	Good
10	Ge <i>et al</i> (2005)	*	*	*	*	*	*	*	*	8	Good
11	Kato <i>et al</i> (2001)	*	*	*	*	*	*	*	*	8	Good
12	Mo <i>et al</i> (2007)	*	*	*	*	*	*	*	*	8	Good

Newcastle-Ottawa quality assessment scale case control studies

Note: A study can be given a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability.

#### Selection

1. Is the case definition adequate?
  - a. Yes, with independent validation\*
  - b. Yes, *e.g.*, record linkage or based on self reports
  - c. No description
2. Representativeness of the cases
  - d. Consecutive or obviously representative series of cases\*
  - e. Potential for selection biases or not stated
3. Selection of Controls
  - f. Community controls\*
  - g. Hospital controls
  - h. No description
4. Definition of Controls
  - i. No history of disease (endpoint)\*
  - j. No description of source

#### Comparability

1. Comparability of cases and controls on the basis of the design or analysis
  - a. Study controls for \_\_\_\_\_ (Select the most important factor.)\*
  - b. Study controls for any additional factor\* (This criteria could be modified to indicate specific control for a second important factor.)

#### Outcome

1. Ascertainment of exposure
  - a. Secure record (*e.g.*, surgical records)\*

*Contd...*

- b. Structured interview where blind to case/control status\*
- c. Interview not blinded to case/control status
- d. Written self-report or medical record only
- e. No description
- 2. Same method of ascertainment for cases and controls
  - f. Yes\*
  - g. No
- 3. Non-Response rate
  - h. Same rate for both groups\*
  - i. Non respondents described
  - j. Rate different and no designation

Thresholds for converting the Newcastle-Ottawa scales to AHRQ standards (good, fair, and poor):

Good quality: 3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain

Fair quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain

Poor quality: 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain

*Reference Source:* Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2021. Available from: [https://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp), assessed on August 2023